Bristol-Myers Squibb stock steadies in the mid-$60s as 2026 EPS guidance and consensus align
Published on 08/31/2026 at 21:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb Inc. (ISIN US1078421011) stock is trading in the mid-$60 range in late August 2026, with recent equity overviews on August 31, 2026 referencing a price of $66.58 per share and a market capitalization of $136.00 billion on the New York Stock Exchange.
The shares have been consolidating close to the prior U.S. trading session’s close of $66.47 on August 30, 2026, leaving Bristol-Myers Squibb valued as a large-cap pharmaceutical name while investors weigh its fiscal 2026 earnings guidance and ongoing strategic options.
Current coverage of earnings projections indicates that management has set a fiscal 2026 earnings per share guidance range of $6.75 to $7.00, while consensus estimates for the same period stand at $6.95, positioning expectations near the upper half of the company’s own outlook.
Guidance range and consensus expectations for 2026 EPS
Recent analyst and earnings overviews highlight that Bristol-Myers Squibb’s fiscal 2026 EPS guidance is framed between $6.75 and $7.00 per share, giving investors a quantitative view of expected profitability for the current year.
Consensus projections compiled alongside this guidance currently center on an EPS figure of $6.95 for fiscal 2026, which sits close to the upper end of the $6.75 to $7.00 guided range and suggests that the broader market expects earnings delivery toward the top of management’s corridor.
The difference between the midpoint of the company’s guidance at $6.875 and the $6.95 consensus view is $0.075 per share, indicating that analyst expectations are modestly above the midpoint rather than materially higher, a nuance that points to steady but measured confidence in Bristol-Myers Squibb’s execution for 2026.
When the latest late-August 2026 share price in the mid-$60s is set against the fiscal 2026 EPS guidance range and the $6.95 consensus estimate, the valuation implies that investors are pricing Bristol-Myers Squibb at a multiple consistent with a mature, cash-generative pharmaceutical business rather than assuming a step change in growth.
Stock performance and late-August 2026 trading context
Per recent market-data snapshots covering the regular U.S. trading session on August 30, 2026, Bristol-Myers Squibb stock was quoted at $66.47, with an intraday range between a low of $66.19 and a high of $67.39 as the shares moved within a relatively tight band.
This late-August 2026 trading range shows the closing price of $66.47 running 0.4 percent above the intraday low of $66.19 and 1.4 percent below the intraday high of $67.39, underscoring a pattern of consolidation where moves are incremental rather than directional.
An equity overview generated on August 31, 2026 referenced Bristol-Myers Squibb at $66.58 per share with a market cap of $136.00 billion, indicating that the stock has remained very close to the prior session’s $66.47 close while the valuation stays in line with other large-cap pharmaceutical peers.
That combination of a stable price range between $66.19 and $67.39 on August 30, 2026 and a subsequent $66.58 reference on August 31, 2026 suggests that Bristol-Myers Squibb shares are currently trading more on fundamental anchors such as guidance and consensus than on short-term volatility or momentum.
For investors, the mid-$60 price region backed by a market cap of $136.00 billion and a fiscal 2026 EPS guidance range of $6.75 to $7.00 provides a compact snapshot of how the market is valuing the company’s near-term earnings power and risk profile.
Analyst stance and earnings framing
Across the latest coverage of Bristol-Myers Squibb, the stock is described as carrying a consensus view that aligns closely with management’s guidance, with the $6.95 EPS estimate for fiscal 2026 embedded as the central point in current projections.
The fact that consensus estimates for fiscal 2026 EPS are only $0.075 above the midpoint of the company’s guided range indicates that analysts broadly see Bristol-Myers Squibb delivering on its plan rather than substantially out- or underperforming it, which in turn supports a valuation anchored to predictable cash flows.
In practical terms, an EPS guidance corridor between $6.75 and $7.00 for fiscal 2026 offers investors a range of outcomes, while the $6.95 consensus near the upper half of the band reflects moderate confidence that the company will land in the top segment of its own expectations.
The current pricing in the mid-$60s, when contrasted with the guided and forecast 2026 EPS levels, implies an earnings multiple that is more reflective of a stable pharmaceutical portfolio and pipeline than of a high-growth narrative, which can influence how investors compare Bristol-Myers Squibb to its peers in the sector.
Key product: immunology and oncology portfolio
Beyond the stock metrics, Bristol-Myers Squibb’s investment case is strongly tied to its portfolio of branded therapies in oncology and immunology, where the company markets a range of treatments that generate recurring revenue streams and underpin its earnings guidance.
These products support the top line and margin structure that make a fiscal 2026 EPS range between $6.75 and $7.00 plausible, since their established positions in treatment guidelines and reimbursement frameworks contribute to visibility on volumes and pricing.
For U.S. retail investors, the product backdrop is a reminder that Bristol-Myers Squibb’s financial story is closely connected to its ability to maintain and grow its franchises in cancer and immune-mediated conditions, even as the late-August 2026 share price remains locked in the mid-$60 zone.
Late-August price level and investor takeaways
As of the latest referenced equity overview on August 31, 2026, Bristol-Myers Squibb stock stands at $66.58 with a market cap of $136.00 billion, anchored on its New York Stock Exchange listing.
This late-August 2026 price level, positioned just above the prior U.S. trading session’s $66.47 close on August 30, 2026 and within a $66.19 to $67.39 intraday range, reinforces the impression of a stock that is consolidating while investors calibrate its fiscal 2026 earnings path.
For investors evaluating Bristol-Myers Squibb, the alignment between the $6.75 to $7.00 fiscal 2026 EPS guidance range, the $6.95 consensus estimate, and the mid-$60 share price provides a clear framework for assessing valuation, expectations and risk in the months ahead.
Read more
More on Bristol-Myers Squibb stock and its fiscal 2026 guidance and consensus can be found in recent earnings and analyst overviews that detail the $6.75 to $7.00 EPS range and the $6.95 forecast for the current year.
Representative therapy portfolio
Bristol-Myers Squibb’s earnings power for fiscal 2026 is linked to its range of therapies in oncology and immunology, where it offers branded treatments used in major indications for U.S. and global patients.
These therapies contribute to recurring revenue that feeds into the earnings per share guidance, supporting the company’s ability to project a $6.75 to $7.00 EPS corridor for fiscal 2026 and underlining why consensus has settled around $6.95 for the same period.
Stock and valuation snapshot
In late August 2026, Bristol-Myers Squibb stock trades on the New York Stock Exchange at a referenced level of $66.58, with a market cap of $136.00 billion as highlighted in an equity overview generated on August 31, 2026.
Against the backdrop of fiscal 2026 EPS guidance between $6.75 and $7.00 and a consensus estimate of $6.95, this mid-$60 price region offers investors a quantified lens for evaluating whether the current valuation adequately reflects Bristol-Myers Squibb’s earnings trajectory and strategic positioning.
Fact box
Company: Bristol-Myers Squibb Inc.
ISIN: US1078421011
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 31, 2026, latest equity overview): $66.58 USD
Market cap: $136.00 billion (as of August 31, 2026)
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
